Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 1998

View Archived Issues

Company Profile: Alexion

Vitamin D3 analogues from Roche for skin, neoplastic diseases

BMS prepares MTP inhibitors for atherosclerosis and related diseases

Roche discloses inhibitors of bacterial dihydrofolate reductase

2,4-Diaminopyrimidines claimed as imaging agents, potentially useful in psychotic disorders

Synaptic develops selective human alpha1A-receptor antagonists

AMPA receptor antagonists disclosed by Pfizer

New anticonvulsants under study at Bristol-Myers Squibb

Somatostatin receptor ligands synthesized by Novo Nordisk

Structure of new IL-6 inhibitors determined at Kitasato Institute

Lipid peroxidation inhibitor discovered in marine sponge by team at Kirin Brewery and U. of Tokyo

OspC-based Lyme disease vaccine proves effective in animal model of chronic disease

Yamanouchi will collaborate on drug R&D with European universities

Antithrombotic agents in stroke indications

Mibefradil inhibits noradrenaline release via blockade of N-type Ca2+ channels

New wave of mergers in store for the pharmaceutical industry?

Glutamate antagonists: a new frontier in stroke research

VasoCare approved in EU

Bronchodilating and antiinflammatory effects of SCA-40 studied in vitro and in vivo

Xerecept shows promise in patients with brain tumors

Aurora sublicenses Sibia drug screening technology to Merck

RiboGene and Dainippon join forces in antibacterial collaboration

Controlled-release oxybutynin to be marketed in Europe by Synthelabo

CBER completes review of Thymoglobulin PLA

Topical interferon alfa enters phase II for intravaginal warts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...